OraSure Technologies Submits COVID-19 Rapid Antigen Prescription Home Self-Test and Professional Test to FDA for Emergency Use Authorization
30 mars 2021 07h00 HE
|
OraSure Technologies, Inc.
BETHLEHEM, Pa., March 30, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it has submitted an application to the U.S. Food and Drug Administration (FDA) for...
OraSure Technologies, Inc. Announces 2020 Full-Year and Fourth Quarter Financial Results and Provides COVID-19 Update
01 mars 2021 16h15 HE
|
OraSure Technologies, Inc.
Full-Year 2020 Net Revenues of $172 Million Increased 11% Year-Over-Year, Driven by $50 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing COVID-19 Rapid Antigen Test...
OraSure Technologies to Present at the Raymond James 42nd Annual Institutional Investors Conference
24 févr. 2021 16h01 HE
|
OraSure Technologies, Inc.
BETHLEHEM, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and...
2020 Fourth Quarter Earnings Conference Call Monday, March 1, 2021, 5:00 p.m. ET
18 févr. 2021 06h00 HE
|
OraSure Technologies, Inc.
BETHLEHEM, Pa., Feb. 18, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 fourth quarter financial results and...
OraSure Subsidiary DNA Genotek’s OMNIgene®·ORAL Included in EUA Granted to Ambry Genetics for Use in COVID-19 RT-PCR Saliva Test
29 janv. 2021 06h00 HE
|
OraSure Technologies, Inc.
BETHLEHEM, Pa., Jan. 29, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and...
OraSure Subsidiary DNA Genotek’s OMNIgene®·ORAL Saliva Collection Device Receives Health Canada Authorization for use in COVID-19 Testing
28 janv. 2021 06h00 HE
|
OraSure Technologies, Inc.
OTTAWA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical...
OraSure’s OMNIgene®·ORAL Saliva Collection Kit Selected by Chronomics for Use in UK Government “Test to Release for International Travel” COVID-19 Testing Program
26 janv. 2021 07h57 HE
|
OraSure Technologies, Inc.
BETHLEHEM, Pa., Jan. 26, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and...
OraSure’s Oragene®•Dx Saliva Collection Kit Included in Industry’s First FDA Authorization for a Whole Exome Sequencing Platform
21 janv. 2021 06h00 HE
|
OraSure Technologies, Inc.
BETHLEHEM, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and...
OraSure Technologies Announces 2021 Annual Meeting Date
08 janv. 2021 06h00 HE
|
OraSure Technologies, Inc.
BETHLEHEM, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT...
OraSure Technologies to Present at the 39th Annual J.P. Morgan Healthcare Conference
05 janv. 2021 06h00 HE
|
OraSure Technologies, Inc.
BETHLEHEM, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and...